[go: up one dir, main page]

MX2007005053A - Metodo para evaluar la enfermedad de alzheimer y reactivo de diagnostico. - Google Patents

Metodo para evaluar la enfermedad de alzheimer y reactivo de diagnostico.

Info

Publication number
MX2007005053A
MX2007005053A MX2007005053A MX2007005053A MX2007005053A MX 2007005053 A MX2007005053 A MX 2007005053A MX 2007005053 A MX2007005053 A MX 2007005053A MX 2007005053 A MX2007005053 A MX 2007005053A MX 2007005053 A MX2007005053 A MX 2007005053A
Authority
MX
Mexico
Prior art keywords
disease
amyloid
alzheimer
diagnostic reagent
immunoassay method
Prior art date
Application number
MX2007005053A
Other languages
English (en)
Inventor
Yuji Yamada
Shigeo Takayama
Original Assignee
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd
Publication of MX2007005053A publication Critical patent/MX2007005053A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
    • G01N33/537—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with separation of immune complex from unbound antigen or antibody
    • G01N33/539—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with separation of immune complex from unbound antigen or antibody involving precipitating reagent, e.g. ammonium sulfate
    • G01N33/541—Double or second antibody, i.e. precipitating antibody
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Neurology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Neurosurgery (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)

Abstract

La presente invencion esta destinada a considerar una tecnica de medicion de un (-amiloide en una muestra biologica tal como sangre, y aplicar la misma al diagnostico de la enfermedad de Alzheimer. La enfermedad de Alzheimer puede ser examinada mediante la medicion del contenido total de (-amiloide 1-42 y fragmentos de (-amiloide 1-42 que tienen la parte C-terminal del (-amiloide 1-42, en un especimen biologico mediante el uso de un metodo de inmunoensayo, en donde un anticuerpo capaz de reconocer la parte C-terminal del (-amiloide 1-42, es empleado. Es preferible que el metodo de inmunoensayo anterior sea un metodo de inmunoensayo competitivo.
MX2007005053A 2004-10-28 2005-10-27 Metodo para evaluar la enfermedad de alzheimer y reactivo de diagnostico. MX2007005053A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2004314639 2004-10-28
JP2005052003 2005-02-25
PCT/JP2005/019787 WO2006046644A1 (ja) 2004-10-28 2005-10-27 アルツハイマー病の検定方法及び診断試薬

Publications (1)

Publication Number Publication Date
MX2007005053A true MX2007005053A (es) 2007-06-19

Family

ID=36227886

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2007005053A MX2007005053A (es) 2004-10-28 2005-10-27 Metodo para evaluar la enfermedad de alzheimer y reactivo de diagnostico.

Country Status (13)

Country Link
US (1) US20080199879A1 (es)
EP (1) EP1813947A4 (es)
JP (1) JPWO2006046644A1 (es)
KR (1) KR20070073778A (es)
CN (1) CN101048662A (es)
AU (1) AU2005297854A1 (es)
BR (1) BRPI0516674A (es)
CA (1) CA2585148A1 (es)
IL (1) IL182540A0 (es)
MX (1) MX2007005053A (es)
NO (1) NO20072206L (es)
RU (1) RU2007119535A (es)
WO (1) WO2006046644A1 (es)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
US7732162B2 (en) 2003-05-05 2010-06-08 Probiodrug Ag Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases
KR101439828B1 (ko) 2005-11-30 2014-09-17 애브비 인코포레이티드 아밀로이드 베타 단백질에 대한 모노클로날 항체 및 이의 용도
JP5475994B2 (ja) 2005-11-30 2014-04-16 アッヴィ・インコーポレイテッド 抗Ａβグロブロマー抗体、その抗原結合部分、対応するハイブリドーマ、核酸、ベクター、宿主細胞、前記抗体を作製する方法、前記抗体を含む組成物、前記抗体の使用及び前記抗体を使用する方法。
SG10201404801YA (en) 2005-12-12 2014-09-26 Ac Immune Sa Monoclonal antibody
ES2409058T3 (es) * 2006-04-13 2013-06-24 Eidia Co., Ltd. Método para someter a prueba la enfermedad de Alzheimer midiendo la tasa de degradación de beta-amiloide en sangre y reactivo de diagnóstico
AR062065A1 (es) 2006-07-14 2008-10-15 Ac Immune Sa Anticuerpo humanizado
JP4683298B2 (ja) * 2006-08-21 2011-05-18 アイシン精機株式会社 被検物質の免疫測定方法、及び免疫結合親和性解析の制御方法
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
WO2008104386A2 (en) 2007-02-27 2008-09-04 Abbott Gmbh & Co. Kg Method for the treatment of amyloidoses
EA200901140A1 (ru) 2007-03-01 2010-04-30 Пробиодруг Аг Новое применение ингибиторов глутаминилциклазы
JP5667440B2 (ja) 2007-04-18 2015-02-12 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤としてのチオ尿素誘導体
US8048420B2 (en) * 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
WO2009016734A1 (ja) * 2007-07-31 2009-02-05 University Of Tsukuba 軽度認知機能障害の検定方法
SG178809A1 (en) * 2007-10-05 2012-03-29 Genentech Inc Use of anti-amyloid beta antibody in ocular diseases
PT2238166E (pt) 2007-10-05 2014-02-11 Genentech Inc Utilização do anticorpo anti-amilóide beta em doenças oculares
JP5185946B2 (ja) * 2007-10-29 2013-04-17 Ｔａｏヘルスライフファーマ株式会社 抗体及びその利用
WO2010034072A1 (en) * 2008-09-26 2010-04-01 The University Of Melbourne Alzheimer's disease biomarkers
CN102695546B (zh) 2009-09-11 2014-09-10 前体生物药物股份公司 作为谷氨酰胺酰环化酶抑制剂的杂环衍生物
AR079443A1 (es) 2009-12-11 2012-01-25 Araclon Biotech Sl Metodos y reactivos para la deteccion mejorada de peptidos beta amiloides
US20130137120A1 (en) * 2010-01-28 2013-05-30 Panasonic Corporation Amyloid b measurement method
US9181233B2 (en) 2010-03-03 2015-11-10 Probiodrug Ag Inhibitors of glutaminyl cyclase
US8269019B2 (en) 2010-03-10 2012-09-18 Probiodrug Ag Inhibitors
ES2684475T3 (es) 2010-04-15 2018-10-03 Abbvie Inc. Proteínas que se unen a beta amiloide
JP5945532B2 (ja) 2010-04-21 2016-07-05 プロビオドルグ エージー グルタミニルシクラーゼの阻害剤としてのベンゾイミダゾール誘導体
MX341369B (es) 2010-07-30 2016-08-17 Genentech Inc * Anticuerpo anti-beta-amiloide humanizado seguro y funcional.
EP3533803B1 (en) 2010-08-14 2021-10-27 AbbVie Inc. Anti-amyloid-beta antibodies
US8530670B2 (en) 2011-03-16 2013-09-10 Probiodrug Ag Inhibitors
EP2511296A1 (en) 2011-04-12 2012-10-17 Araclón Biotech, S. L. Antibody, kit and method for determination of amyloid peptides
WO2012142300A2 (en) * 2011-04-12 2012-10-18 Quanterix Corporation Methods of determining a treatment protocol for and/or a prognosis of a patient's recovery from a brain injury resulting from a hypoxic event
WO2012142301A2 (en) 2011-04-12 2012-10-18 Quanterix Corporation Methods of determining a treatment protocol for and/or a prognosis of a patients recovery from a brain injury
US9541561B2 (en) 2012-06-14 2017-01-10 Electronics And Telecommunications Research Institute Method for diagnosing Alzheimer's disease using biomaterial
JP5991666B2 (ja) * 2012-07-04 2016-09-14 公立大学法人大阪市立大学 アルツハイマー病を検出する方法及びキット
JP2016103980A (ja) * 2013-03-08 2016-06-09 パナソニックヘルスケア株式会社 ハイブリドーマ及びモノクローナル抗体
US11360098B2 (en) * 2015-09-28 2022-06-14 Quest Diagnostics Investments Llc Amyloid beta detection by mass spectrometry
WO2017141881A1 (ja) * 2016-02-15 2017-08-24 ノーベルファーマ株式会社 遺伝性疾患に関わるタンパク質の測定方法及び測定キット
EP3242134A1 (en) * 2016-05-04 2017-11-08 Euroimmun Medizinische Labordiagnostika AG Assay for the diagnosis of a neurological disease
PL3461819T3 (pl) 2017-09-29 2020-11-30 Probiodrug Ag Inhibitory cyklazy glutaminylowej
EP4307988A4 (en) * 2021-03-16 2025-01-22 NeuroVision Imaging, Inc. BIOFLUID-BASED METHODS FOR DIAGNOSING CONDITIONS ASSOCIATED WITH ALZHEIMER'S DISEASE
CN113311153B (zh) * 2021-05-12 2023-05-26 华中科技大学 一种用于阿尔茨海默病诊疗一体化的多功能的纳米粒子

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0411974A1 (en) * 1989-07-05 1991-02-06 N.V. Innogenetics S.A. Monoclonal antibodies to a neurofibrillary tangle antigen
US6610493B1 (en) * 1993-06-17 2003-08-26 Brigham And Women's Hospital Screening compounds for the ability to alter the production of amyloid-β peptide
US5786180A (en) * 1995-02-14 1998-07-28 Bayer Corporation Monoclonal antibody 369.2B specific for β A4 peptide
DE50103881D1 (de) * 2001-06-12 2004-11-04 Wiltfang Jens Monoklonaler Antikörper, mbAb 1E8, welcher für die zwei ersten N-terminalen Aminosäuren von Amyloid-beta-Peptiden spezifisch ist und dessen Verwendung zum Nachweis von Amyloid-beta Peptiden und/oder sAPPa
WO2003018050A1 (en) * 2001-08-10 2003-03-06 Merck & Co., Inc. Gamma three protease
JP2005532276A (ja) * 2002-03-05 2005-10-27 ラモト アト テル−アヴィヴ ユニバーシティ リミテッド 免疫化組成物およびアミロイド前駆体タンパク質のβ−セクレターゼ開裂部位に対する免疫応答を誘発する方法

Also Published As

Publication number Publication date
AU2005297854A1 (en) 2006-05-04
EP1813947A4 (en) 2008-06-11
NO20072206L (no) 2007-07-30
RU2007119535A (ru) 2008-12-10
WO2006046644A1 (ja) 2006-05-04
IL182540A0 (en) 2007-09-20
CN101048662A (zh) 2007-10-03
KR20070073778A (ko) 2007-07-10
BRPI0516674A (pt) 2008-09-16
CA2585148A1 (en) 2006-05-04
US20080199879A1 (en) 2008-08-21
JPWO2006046644A1 (ja) 2008-05-22
EP1813947A1 (en) 2007-08-01

Similar Documents

Publication Publication Date Title
MX2007005053A (es) Metodo para evaluar la enfermedad de alzheimer y reactivo de diagnostico.
WO2005012553A3 (en) Optical in vivo probe of analyte concentration within the sterile matrix under the human nail
BRPI0411059A (pt) tiras de teste diagnóstico para detecção de um analito de interesse em uma amostra lìquida, para detecção de anticorpo de anti-hiv em uma amostra, e de teste de gravidez de imuno-diagnóstico, e, método de detecção de um anticorpo de interesse em uma amostra lìquida
GB0510943D0 (en) Improved immunoassay methods
ATE411525T1 (de) Nachweis einer histonmodifikation in zellfreien nukleosomen
EP2124053A1 (en) Biological information acquisition method and instrument, and physiologically-active substance measurement method and instrument
AR107561A2 (es) Ensayo elisa para la detección de vegf
WO2006026020A3 (en) Oncofetal fibronectin as a marker for disease and other conditions and methods for detection of oncofetal fibronectin
WO2006127861A3 (en) Diagnosis of diseases and conditions by analysis of histopathologically processed biological samples using liquid tissue preparations
WO2008039949A3 (en) Integrated sensor for analyzing biological samples
DE602008000117D1 (de) Verfahren zur selektiven bestimmung von procalcitonin 1-116 für diagnostische zwecke sowie antikörper und kits zur ausführung dieses verfahrens
WO2008014132A3 (en) Combination analyte measurement device and method of use
WO2009021131A3 (en) System and method for biological sample collection and analyte detection
Sanchez et al. Factors influencing the prevalence of Salmonella spp. in swine farms: a meta-analysis approach
WO2014074835A8 (en) Antibody compositions and immunoassay methods to detect isoforms of anti-mullerian hormone
DE502007004873D1 (de) Probengewinnungssystem zum gewinnen einer flüssigen probe
WO2006119292A3 (en) Methods for detection of biological substances
NZ592819A (en) Thyroid analyte detection and measurement
WO2005098433A3 (en) Diagnostic assays for alzheimer’s disease
WO2005044989A3 (en) Polynucleotides and polypeptides of anaplasma phagocytophilum and methods of using the same
WO2007024735A3 (en) Method and antibodies for detecting nitrofuran
WO2009016734A1 (ja) 軽度認知機能障害の検定方法
Fan et al. Fingernail analysis in diagnosis and management of diabetes mellitus
DE602004026869D1 (de) Diagnose von leberzirrhose mittels eines für menschliches protoonkogenes protein spezifischen antikörpers
ATE437182T1 (de) Diagnose von allergischen erkrankungen, atopischen erkrankungen und/oder autoimmunerkrankungen durch nachweis von autoantikörpern gegen cd28 in humanem serum

Legal Events

Date Code Title Description
GB Transfer or rights